Literature DB >> 17876884

Sirolimus-related pulmonary toxicity mimicking 'asthma like' symptoms.

G-L Gupte1, S Mahadevan, J-R Clarke, H Alton, S-V Beath.   

Abstract

Sirolimus is an immunosuppressant with expanding use in pediatric organ transplantation, dermatology and rheumatology. We report two cases of children who developed asthma like symptoms and were diagnosed with interstitial lung disease, which responded to discontinuation of sirolimus. Pediatricians should be aware about the pulmonary side effects of sirolimus.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17876884      PMCID： PMC4434648          DOI： 10.3748/wjg.v13.i38.5151

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN： 1007-9327            Impact factor:   5.742


  7 in total

1.  Interstitial pneumonitis associated with sirolimus therapy in renal-transplant recipients.

Authors:  S J Singer; R Tiernan; E J Sullivan
Journal:  N Engl J Med       Date:  2000-12-14       Impact factor: 91.245

2.  Four cases of sirolimus-associated interstitial pneumonitis: identification of risk factors.

Authors:  C Morath; V Schwenger; D Ksoll-Rudek; C Sommerer; J Beimler; J Schmidt; M Zeier
Journal:  Transplant Proc       Date:  2007 Jan-Feb       Impact factor: 1.066

3.  Characteristics of sirolimus-associated interstitial pneumonitis in renal transplant patients.

Authors:  E Morelon; M Stern; D Israël-Biet; J M Correas; C Danel; M F Mamzer-Bruneel; M N Peraldi; H Kreis
Journal:  Transplantation       Date:  2001-09-15       Impact factor: 4.939

4.  Interstitial pneumonitis associated with sirolimus (rapamycin) therapy after liver transplantation.

Authors:  A Lennon; K Finan; M X FitzGerald; P A McCormick
Journal:  Transplantation       Date:  2001-09-27       Impact factor: 4.939

Review 5.  The macrolide immunosuppressants in dermatology: mechanisms of action.

Authors:  Alexander M Marsland; Christopher E M Griffiths
Journal:  Eur J Dermatol       Date:  2002 Nov-Dec       Impact factor: 3.328

Review 6.  Newer immunosuppressive drugs: their potential role in rheumatoid arthritis therapy.

Authors:  Alexandros A Drosos
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Sirolimus-associated pulmonary toxicity.

Authors:  Phuong-Thu T Pham; Phuong-Chi T Pham; Gabriel M Danovitch; David J Ross; H Albin Gritsch; Elizabeth A Kendrick; Jennifer Singer; Tariq Shah; Alan H Wilkinson
Journal:  Transplantation       Date:  2004-04-27       Impact factor: 4.939
  7 in total
  3 in total

1.  Sirolimus associated pneumonitis after nonmyeloablative peripheral blood stem cell transplant for sickle cell disease.

Authors:  Matthew M Hsieh; M Beth Link; John F Tisdale
Journal:  Biol Blood Marrow Transplant       Date:  2008-02       Impact factor: 5.742

2.  Rapamycin decreases airway remodeling and hyperreactivity in a transgenic model of noninflammatory lung disease.

Authors:  Elizabeth L Kramer; William D Hardie; Elizabeth M Mushaben; Thomas H Acciani; Patricia A Pastura; Thomas R Korfhagen; Gurjit Khurana Hershey; Jeffrey A Whitsett; Timothy D Le Cras
Journal:  J Appl Physiol (1985)       Date:  2011-09-08

Review 3.  Interstitial Lung Disease Associated with mTOR Inhibitors in Solid Organ Transplant Recipients: Results from a Large Phase III Clinical Trial Program of Everolimus and Review of the Literature.

Authors:  Patricia Lopez; Sven Kohler; Seema Dimri
Journal:  J Transplant       Date:  2014-12-18
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.